Influence of obesity on breast density reduction by omega-3 fatty acids: Evidence from a randomized clinical trial

Cancer Prevention Research

Volumn 9, Issue 4, 2016, Pages 275-282

  Sandhu, Narinder ^a   Schetter, Susann E ^a   Liao, Jason ^a   Hartman, Terryl J ^b   Richie, John P ^a   McGinley, John ^c   Thompson, Henry J ^c   Prokopczyk, Bogdan ^a   DuBrock, Cynthia ^d   Signori, Carina ^a   Hamilton, Christopher ^a   Calcagnotto, Ana ^a   Trushin, Neil ^a   Aliaga, Cesar ^a   Demers, Laurence M ^a   El Bayoumy, Karam ^a   Manni, Andrea ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; RALOXIFENE; TAMOXIFEN; TRIACYLGLYCEROL; ANTIESTROGEN; DRUG COMBINATION; ICOSAPENTAENOIC ACID;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; BREAST DENSITY; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENERGY CONSUMPTION; ENERGY EXPENDITURE; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDY; MACRONUTRIENT; MAJOR CLINICAL STUDY; NORMAL HUMAN; OBESITY; OPEN STUDY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; BREAST; BREAST NEOPLASMS; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; DRUG COMBINATION; FOLLOW UP; MAMMOGRAPHY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; BODY MASS INDEX; BREAST; BREAST DENSITY; BREAST NEOPLASMS; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAMMOGRAPHY; MIDDLE AGED; OBESITY; RALOXIFENE HYDROCHLORIDE; TAMOXIFEN;

EID: 84964059148     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0235     Document Type: Article

References (46)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
2. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial.Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
3. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010;28:3090-5.
4. Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19:443-6.
5. Manni A, Xu H, Washington S, Aliaga C, Cooper T, Richie JP Jr, et al. The impact of fish oil on the chemopreventive efficacy of tamoxifen against development of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Cancer Prev Res 2010;3:322-30.
6. Manni A, Richie JPJr, Xu H, Washington S, Aliaga C, Bruggeman R, et al. Influence of omega-3 fatty acids on Tamoxifen-induced suppression of rat mammary carcinogenesis. Int J Cancer 2014;134:1549-57.
7. Jiang W, Zhu Z, McGinley JN, El-Bayoumy K, Manni A, Thompson HJ. Identification of a molecular signature underlying inhibition of mammary carcinoma growth by dietary N-3 fatty acids. Cancer Res 2012; 72:3795-806.
8. Bidinotto LT, de Cicco RL, Vanegas JE, Santucci-Pereira J, VandenHeuvel JP, Washington S, et al. Fish oil alters tamoxifen-modulated expression of mRNAs that encode genes related to differentiation, proliferation, metastasis, and immune response in rat mammary tumors. Nutr Cancer 2012; 64:991-9.
9. Skibinski CG, Thompson HJ, Das A, Manni A, Bortner JD, Stanley A, et al. Proteomic changes induced by effective chemopreventive ratios of n-3:n-6 fatty acids and tamoxifen against MNU-induced mammary cancer in the rat. Cancer Prev Res 2013;6:979-88.
10. Ruxton CH, Reed SC, Simpson MJ, Millington KJ. The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 2007;20:275-85.
11. Signori C, El-Bayoumy K, Russo J, Thompson HJ, Richie JP, Hartman TJ, et al. Chemoprevention of breast cancer by fish oil in preclinical models: trials and tribulations. Cancer Res 2011;71:6091-6.
12. Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23:1946-57.
13. White PJ, Arita M, Taguchi R, Kang JX, Marette A. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 2010;59:3066-73.
14. Flachs P, Ruhl R, Hensler M, Janovska P, Zouhar P, Kus V, et al. Synergistic induction of lipid catabolism and anti-inflammatory lipids in white fat of dietary obese mice in response to calorie restriction and n-3 fatty acids. Diabetologia 2011;54:2626-38.
15. Puglisi MJ,Hasty AH, Saraswathi V. The role of adipose tissue inmediating the beneficial effects of dietary fish oil. J Nutr Biochem 2010;22:101-8.
16. Chajes V, Torres-Mejia G, Biessy C, Ortega-Olvera C, Angeles-Llerenas A, Ferrari P, et al. omega-3 and omega-6 Polyunsaturated fatty acid intakes and the risk of breast cancer in Mexican women: impact of obesity status. Cancer Epidemiol Biomarkers Prev 2012;21:319-26.
17. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction inmammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011; 103:744-52.
18. Signori C, DuBrock C, Richie JP, Prokopczyk B, Demers LM, Hamilton C, et al. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. Eur J Clin Nutr 2012;66:878-84.
19. NCI. ∗Diet∗Calc Analysis Program, Version 1.4.3. National Cancer Institute, Applied Research Program. November 2005. 2005; Available from: http://riskfactor.cancer.gov/DHQ/dietcalc/
20. International Physical Activity Questionnaire. Available from: https://sites.google.com/site/theipaq/
21. Craig CL, Marshall AL, SjostromM, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381-95.
22. Schetter SE, Hartman TJ, Liao J, Richie JP, Prokopczyk B, DuBrock C, et al. Differential impact of body mass index on absolute and percent breast density: implications regarding their use as breast cancer risk biomarkers. Breast Cancer Res Treat 2014;146:355-63.
23. Highnam B, Yaffe, Karssemeijer, Harvey. Robust breast composition measures-VolparaTM. Digital Mammography: Lecture Notes on Computer Science 2010;6136:342-9.
24. MartĀ J, Oliver A, Freixenet J, MartĀ R, Jeffreys M, Harvey J, et al. Comparing a new volumetric breast density method (VolparaTM) to Cumulus. Digital Mammography: Berlin Heidelberg: Springer; 2010. p.408-13.
25. Woolcott CG, Courneya KS, Boyd NF, Yaffe MJ, Terry T, McTiernan A, et al. Mammographic density change with 1 year of aerobic exercise among postmenopausalwomen: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2010;19:1112-21.
26. Manni A, Richie JPJr, Xu H, Washington S, Aliaga C, Cooper TK, et al. Effects of fish oil and Tamoxifen on preneoplastic lesion development and biomarkers of oxidative stress in the early stages of N-methyl-Nnitrosourea-induced rat mammary carcinogenesis. Int J Oncol 2011; 39:1153-64.
27. Cuzick J, Warwick J, Pinney E,Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-8.
28. Fox J, Weisberg S. An R companion to applied regression, Chapter 6. 2nd ed: Sage; 2011.
29. Lawlor DA, Okasha M, Gunnell D, Smith GD, Ebrahim S. Associations of adult measures of childhood growth with breast cancer: findings from the British Women's Heart and Health Study. Br J Cancer 2003;89:81-7.
30. Hunter DJ, Willett WC. Diet, body size, and breast cancer. Epidemiol Rev 1993;15:110-32.
31. Ekbom A, Thurfjell E, Hsieh CC, Trichopoulos D, Adami HO. Perinatal characteristics and adult mammographic patterns. Int J Cancer 1995; 61:177-80.
32. Noguchi M, Minami M, Yagasaki R, Kinoshita K, Earashi M, Kitagawa H, et al. Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. Br J Cancer 1997;75:348-53.
33. Yuri T, Danbara N, Tsujita-Kyutoku M, Fukunaga K, Takada H, Inoue Y, et al. Dietary docosahexaenoic acid suppresses N-methyl-N-nitrosoureainduced mammary carcinogenesis in rats more effectively than eicosapentaenoic acid. Nutr Cancer 2003;45:211-7.
34. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
35. Stuedal A, Ma H, Bjorndal H, Ursin G. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. Climacteric 2009;12:248-58.
36. Atkinson C, Warren R, Bingham SA, Day NE.Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8:863-6.
37. Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 2012;14: R102.
38. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of theNational Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 2010;3:696-706.
39. Eilertsen AL, Karssemeijer N, Skaane P, Qvigstad E, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. BJOG 2008;115:773-9.
40. Jackson VP, San Martin JA, Secrest RJ, McNabb M, Carranza-Lira S, Figueroa-Casas P, et al. Comparison of the effect of raloxifene and continuouscombined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women. Am J Obstet Gynecol 2003;188: 389-94.
41. FreedmanM, San Martin J, O'Gorman J, Eckert S, Lippman ME, Lo SC, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-6.
42. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KP, Kelekis DA, Creatsas GC. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002;9:110-6.
43. Burstein HJ, Prestrud AA, Seidenfeld J, AndersonH, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptorpositive breast cancer. J Clin Oncol 2010;28:3784-96.
44. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:2206-23.
45. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006;98:1285-91.
46. Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, et al. Mammographic breast density response to aromatase inhibition. Clin Cancer Res 2013;19:2144-53.